MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 - Macrogenics ( NASDAQ:MGNX )

4 days ago

Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR Patients remained on vobra duo through a median of 6 doses ( ranging up to 12 ) , representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohort

Ticker	Sentiment	Impact
MGNX	Neutral	20 %